BRPI1007222A2 - agente de depleção de células b para tratamento de aterosclerose - Google Patents

agente de depleção de células b para tratamento de aterosclerose

Info

Publication number
BRPI1007222A2
BRPI1007222A2 BRPI1007222A BRPI1007222A BRPI1007222A2 BR PI1007222 A2 BRPI1007222 A2 BR PI1007222A2 BR PI1007222 A BRPI1007222 A BR PI1007222A BR PI1007222 A BRPI1007222 A BR PI1007222A BR PI1007222 A2 BRPI1007222 A2 BR PI1007222A2
Authority
BR
Brazil
Prior art keywords
cell depletion
treating atherosclerosis
depletion agent
agent
atherosclerosis
Prior art date
Application number
BRPI1007222A
Other languages
English (en)
Inventor
Alain Tedgui
Hafid Ait-Oufella
Thomas Tedder
Ziad Mallat
Original Assignee
Inserm Inst Nat De La Santé Et De La Rech Médicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inserm Inst Nat De La Santé Et De La Rech Médicale filed Critical Inserm Inst Nat De La Santé Et De La Rech Médicale
Publication of BRPI1007222A2 publication Critical patent/BRPI1007222A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI1007222A 2009-01-06 2010-01-05 agente de depleção de células b para tratamento de aterosclerose BRPI1007222A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09290005 2009-01-06
EP09305013 2009-01-07
PCT/EP2010/050048 WO2010079161A1 (en) 2009-01-06 2010-01-05 A b cell depleting agent for the treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
BRPI1007222A2 true BRPI1007222A2 (pt) 2016-02-23

Family

ID=41651536

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007222A BRPI1007222A2 (pt) 2009-01-06 2010-01-05 agente de depleção de células b para tratamento de aterosclerose

Country Status (9)

Country Link
US (4) US20110275791A1 (pt)
EP (1) EP2373339B1 (pt)
JP (1) JP5828151B6 (pt)
KR (1) KR20110117652A (pt)
CN (1) CN102271710A (pt)
BR (1) BRPI1007222A2 (pt)
CA (1) CA2744670C (pt)
ES (1) ES2630226T3 (pt)
WO (1) WO2010079161A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102625804B (zh) * 2009-06-12 2015-04-08 Abivax公司 用于治疗aids的化合物
JP7012366B2 (ja) * 2016-10-19 2022-02-14 公立大学法人横浜市立大学 抗動脈硬化剤及び動脈硬化の病態判定方法
CN120847420B (zh) * 2025-09-23 2025-12-02 天津医科大学总医院 T细胞亚群在制备评估b细胞耗竭疗法试剂盒中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
KR100944575B1 (ko) * 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
WO2004075789A2 (en) 2003-02-26 2004-09-10 Cook Incorporated PROTHESIS ADAPTED FOR PLACEDd UNDER EXTERNAL IMAGING
ME00426B (me) 2003-04-09 2011-10-10 Genentech Inc Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
JP2007514787A (ja) 2003-12-19 2007-06-07 ジェネンテック・インコーポレーテッド 自己免疫疾患の治療におけるcd20の検出
EP1740946B1 (en) * 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US20060188495A1 (en) * 2005-01-13 2006-08-24 Genentech, Inc. Treatment method
WO2007053661A2 (en) 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
JP5470261B2 (ja) 2007-11-02 2014-04-16 アンセルム(アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル) 大動脈瘤非ヒト動物モデルの作出方法
EP2331564A4 (en) * 2008-10-06 2013-02-20 Carolus Therapeutics Inc PROCESS FOR TREATMENT OF IGNITION
PE20120359A1 (es) * 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
US9688767B2 (en) * 2013-03-15 2017-06-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of predicting survival time in myocardial infarction patients by measuring BAFF levels

Also Published As

Publication number Publication date
JP2012514587A (ja) 2012-06-28
US20200376118A1 (en) 2020-12-03
JP5828151B2 (ja) 2015-12-02
KR20110117652A (ko) 2011-10-27
CA2744670A1 (en) 2010-07-15
JP5828151B6 (ja) 2018-09-19
US20130224215A1 (en) 2013-08-29
US20190365890A1 (en) 2019-12-05
CA2744670C (en) 2018-05-15
ES2630226T3 (es) 2017-08-18
US20110275791A1 (en) 2011-11-10
EP2373339A1 (en) 2011-10-12
US12144859B2 (en) 2024-11-19
EP2373339B1 (en) 2017-04-19
CN102271710A (zh) 2011-12-07
WO2010079161A1 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
BRPI1013219A2 (pt) método para o alvejamento-branqueamento enzimático têxtil
BRPI0908970A2 (pt) Método para controlar interferência em implementação de célula femto
PT2499249T (pt) Moléculas antisentido e métodos para tratar patologias
PT2528699T (pt) Aparelho e processo para tratamento de resíduos
BRPI1014721A2 (pt) métodos e dispositivos para cortar e raspar tecido
IL225924A (en) Dlbcl treatment
BRPI0911077A2 (pt) método para tratamento de biomassa
BR112013018679A2 (pt) agente para o tratamento da alopecia
BR112013016491A2 (pt) método para tratamento de têxtil
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BRPI1014981A2 (pt) material para mancais de contato deslizante
BR112012005036A2 (pt) equipamento para o processamento de material de descarte.
BR112012005247A2 (pt) agente antifitoviral
BRPI1008795A2 (pt) processos de alquilação e de hidroconversão
BR112014015551A2 (pt) método para tratar lama e método para desidratação de lama
BRPI1013927A2 (pt) métodos e composições para o tratamento de lúpus
BRPI1013361A2 (pt) método para evitar e tratar hipermeabilidade.
BRPI0924398A2 (pt) perexilina, metodo de tratamento de hfnef e programa de tratamento para tratar hfnef
BRPI1008016A2 (pt) método para o tratamento de águas residuais
BRPI1009435A2 (pt) tratamento para câncer no pâncreas
EG26972A (en) Method for treating waste
CO6920300A2 (es) Agente de dispersión para suspensiones sólidas
BR112013009075A2 (pt) método e arranjo para tratamento de polpa
PL2830775T3 (pl) Sposób przetwarzania odpadów, zwłaszcza odpadów z gospodarstw domowych i instalacja do stosowania tego sposobu
BRPI1014778A2 (pt) dispositivo para processar algodão

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.